肾癌循环肿瘤细胞检测及临床应用的研究进展  

Progress in detection and clinical application of circulating tumor cells in renal cell carcinoma

作　　者：杜鑫 洪保安 赵强[1] 纪永鹏 杨勇[1] 张宁[1] Du Xin;Hong Baoan;Zhao Qiang;Ji Yongpeng;Yang Yong;Zhang Ning(Department of Urology,Peking University Cancer Hospital&lnstitme,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所泌尿外科,恶性肿瘤发病机制及转化研究教育部重点实验室,100142

出　　处：《中华泌尿外科杂志》2020年第2期153-156,共4页Chinese Journal of Urology

摘　　要：肾癌是泌尿系统常见的恶性肿瘤之一。其中20%~30%的患者会出现远处转移。但目前用于肾癌诊断、监测复发和评估预后的生物标志物仍不确定。循环肿瘤细胞(CTCs)是从原发肿瘤或转移灶脱落、侵入并存在于外周血管的肿瘤细胞。因此CTCs被认为是肿瘤转移的关键环节。然而,目前肾癌CTCs的相关研究面临检测方法不统一、临床应用较局限等问题。本文就肾癌CTCs检测和临床应用的研究进展作一综述。Renal cell carcinoma is one of the common malignant tumors in genitourinary cancer.20%-30%of patients have distant metastases.However,current biomarkers used for diagnosis,recurrence monitoring,and prognosis assessment are still uncertain.Circulating tumor cells(CTCs)are tumor cells that are detached from the primary tumor or metastases,and invade and presenting in peripheral blood vessels.Therefore,CTCs is regarded as a key step in the process of tumor metastasis.However,current studies on CTCs of renal cell carcinoma are facing with problems such as inconsistent detection methods and limited clinical applications.This article reviews the progress in the detection and clinical application of CTCs of renal cell carcinoma.

关 键 词：癌 肾细胞 循环肿瘤细胞 生物标志物 

分 类 号：R737.11[医药卫生—肿瘤]